Table 1. Patients characteristics.
| Variable | |
|---|---|
| N= | 392 |
| Median age | 70y (37-95) |
| Male Gender | 134 (34%) |
| WHO classification | |
| RA/ del5q | 125 (32%) / 97 (25%) |
| RARS/RCMD | 27 (7%) /41 (10%) |
| RAEB-1 | 91 (23%) |
| Other | 11 (3%) |
| Therapy related MDS | 61 (16%) |
| Median BM blast count (%) | 3 (0-9) |
| Deletion (5q) | |
| isolated | 230 (61%) |
| Del(5q)+1 aberration | 105 (24%) |
| Complex K including del(5q) | 42 (11%) |
| FISH only | 15 (4%) |
| RBC TD before LEN | 353 (90%) |
| Use of ESA before LEN | 155 (39%) |
| IPSS low/intermediate-1 | 161 (41%) /231 (59%) |
| Use of HMA before LEN | 13 (3%) |
| LEN response | 210 (54%) |
| LEN initial dose 10mg daily | 296 (76%) |
| LEN duration | 9.5m (1-68) |
M/F: male/female, RA: refractory anemia, del5q: 5q syndrome, RARS: refractory anemia with ring sideroblasts, RCMD: Refractory cytopenia with multilineage dysplasia, RAEB: Refractory anemia with excess of blast, BM: bone marrow, K.: karyotype, RBC: Red blood cell, TD:transfusion dependency, LEN: lenalidomide, ESA: erythropoiesis stimulating agent, HMA: hypomethylating agents, m: month